

Hyperthermia system made in Japan helping cancer patients in Vietnam

03 October 2022 | News

Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by GN Corporation

Treatment of cancer using one's own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional chemotherapy, radiotherapy and surgery, practiced in Japan for long is now offered in Vinmec hospital, Hanoi, Vietnam, following technology transfer by GN Corporation.

Cancer patients from neighboring countries are now visiting Vinmec hospital for this treatment. Autologous immune-cell therapy, regulated by the regenerative medicine law in Japan, uses lab-expanded autologous immune cells, without animal proteins or genetic manipulation.

While increase in survival rate in cancer patients is reported by adding immune-cell therapy to conventional treatment regimen, the Hyperthermia system developed in Japan further improves outcome of cancer treatment as it targets the cancer cells, vulnerable to damage at a higher temperature of 42 Deg Celsius.

To propagate these add-on cancer treatments to overseas hospitals, GNC Japan is collaborating with Yamamoto Vinita, manufacturers of Thermotron, the first hyperthermia equipment to treat malignant tumors, approved in Japan, installed in more than 300 hospitals in six countries, till date. The latest Thermotron-RF8-EX version is a stand-alone system with Eight MHZ radiofrequency, uses electrodes of different sizes in combination to treat superficial and deep-seated solid tumors of the entire body except eye and brain.